A case study on the value of access to novel therapies through clinical trials
62% of patients were progression-free at 18 months post-transplantation
Study findings presented at ASCO 2019
Cleveland Clinic researchers study new treatments for rare disease
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy